The etiology of rare gastric diseases is intricate, involving genetics, diet, excessive smoking and drinking, environmental influences, and bacterial infections. Rare gastric diseases pose complex challenges due to their low occurrence rates and varied presentations. Our company has expertise and capabilities in the field of rare gastric diseases and focuses on offering comprehensive drug development services for researchers and scientists.

Overview of Gastric Diseases

The stomach, positioned between the esophagus and small intestine, is susceptible to various conditions such as chronic gastritis, gastric ulcers, and gastric cancer. Gastropathy types encompass acute hemorrhagic erosive gastropathy, reactive gastropathy, congestive gastropathy, and hypertrophic gastropathy. Common symptoms include nausea, bloating, diarrhea, and abdominal pain.

The pathogenesis of rare gastric diseases involves intricate interactions among genetic, environmental, and immunological factors, leading to the manifestation of complex and challenging conditions. Here are key aspects of the pathogenesis of rare gastric diseases.

• Genetic Factors: Some rare gastric diseases have a genetic component, where mutations in specific genes predispose individuals to these conditions.
• Autoimmune Responses: Certain rare gastric diseases result from the immune system mistakenly targeting the cells of the stomach lining.
• Infectious Agents: Infections with certain bacteria, viruses, or parasites can lead to rare gastric diseases.
• Metabolic Abnormalities: Rare gastric diseases can also stem from metabolic irregularities affecting the stomach.

Fig.1 Pathophysiology and therapeutic of functional dyspepsia. (Koga Y. 2022)

Therapeutics Development for Gastric Diseases

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Our team comprises experts with in-depth knowledge of rare stomach diseases, including their pathophysiology, therapeutic options, and the latest research developments. We provide personalized services for diagnostics, therapeutic, and disease model development, catering specifically to the requirements of researchers and scientists specializing in rare stomach diseases.

Types of Gastric Diseases

Therapeutic and Animal Model Development Services

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic

Animal Model Development Services

• Genetically Engineering Model Development
• Humanized Animal Model Development
• Induced Disease Model
• Surgery Model
• Syngeneic Model
• Xenograft Model

Equipped with advanced facilities and the latest technologies, our company provides comprehensive preclinical research services including pharmacology, pharmacokinetics, and drug safety evaluation to aid drug discovery and development processes. We aim to expedite the development of innovative therapeutics that enhance outcomes and quality of life for individuals with rare gastric diseases. If you are interested in our services, please contact us for further information and pricing details.

Reference

• Koga, Yasuhiro. "Microbiota in the stomach and application of probiotics to gastroduodenal diseases." World journal of gastroenterology 28.47 (2022): 6702-6715.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.